Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

372 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Commercial Immunoglobulin Products Contain Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein.
Upasani V, Townsend K, Wu MY, Carr EJ, Hobbs A, Dowgier G, Ragno M, Herman LS, Sharma S, Shah D, Lee SFK, Chauhan N, Glanville JM, Neave L, Hanson S, Ravichandran S, Tynan A, O'Sullivan M, Moreira F, Workman S, Symes A, Burns SO, Tadros S, Hart JCL, Beale RCL, Gandhi S, Wall EC, McCoy L, Lowe DM. Upasani V, et al. Among authors: ravichandran s. Clin Infect Dis. 2023 Oct 5;77(7):950-960. doi: 10.1093/cid/ciad368. Clin Infect Dis. 2023. PMID: 37338118 Free PMC article.
A phase 1b dose-escalation study of carfilzomib in combination with thalidomide and dexamethasone in patients with relapsed/refractory systemic immunoglobulin light chain amyloidosis.
Ravichandran S, Hall A, Jenner M, Garg M, Kishore B, Lachmann H, Gillmore J, Pitchford A, Oughton JB, Mahmood S, Sachchithantham S, Hawkins P, Brown S, Wechalekar A. Ravichandran S, et al. Amyloid. 2023 Sep;30(3):290-296. doi: 10.1080/13506129.2023.2169124. Epub 2023 May 22. Amyloid. 2023. PMID: 37216268 Clinical Trial.
Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis.
Cohen OC, Brodermann MH, Blakeney IJ, Mahmood S, Sachchithanantham S, Ravichandran S, Law S, Lachmann HJ, Whelan CJ, Popat R, Rabin N, Yong K, Kyriakou C, Shah R, Cheesman S, Worthington S, Hawkins P, Gillmore JD, Wechalekar AD. Cohen OC, et al. Among authors: ravichandran s. Amyloid. 2020 Sep;27(3):200-205. doi: 10.1080/13506129.2020.1765768. Epub 2020 May 15. Amyloid. 2020. PMID: 32408823 Clinical Trial.
Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis.
Bomsztyk J, Ravichandran S, Giles HV, Wright N, Berlanga O, Khwaja J, Mahmood S, Wisniowski B, Cohen O, Foard D, Gilbertson J, Rauf MU, Starr N, Martinez-Naharro A, Venneri L, Whelan C, Fontana M, Hawkins PN, Gillmore JD, Lachmann H, Harding S, Pratt G, Wechalekar AD. Bomsztyk J, et al. Among authors: ravichandran s. Blood. 2024 Mar 28;143(13):1259-1268. doi: 10.1182/blood.2023022399. Blood. 2024. PMID: 38194690
Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real-world longitudinal data.
Ravichandran S, Cohen OC, Law S, Sachchithanantham S, Mahmood S, Foard D, Fontana M, Martinez-Naharro A, Whelan C, Gillmore JD, Lachmann HJ, Hawkins PN, Wechalekar AD. Ravichandran S, et al. Br J Haematol. 2021 Aug;194(3):587-597. doi: 10.1111/bjh.17636. Epub 2021 Jun 29. Br J Haematol. 2021. PMID: 34189728
Prognostic importance of the 6 min walk test in light chain (AL) amyloidosis.
Cohen OC, Sathyanath A, Petrie A, Ravichandran S, Law S, Manwani R, Foard D, Sachchithanantham S, Mahmood S, Martinez-Naharro A, Fontana M, Whelan CJ, Hawkins PN, Lachmann HJ, Gillmore JD, Wechalekar AD. Cohen OC, et al. Among authors: ravichandran s. Heart. 2022 Sep 26;108(20):1616-1622. doi: 10.1136/heartjnl-2021-320703. Heart. 2022. PMID: 35764371
The experience of hereditary apolipoprotein A-I amyloidosis at the UK National Amyloidosis Centre.
Cohen OC, Blakeney IJ, Law S, Ravichandran S, Gilbertson J, Rowczenio D, Mahmood S, Sachchithanantham S, Wisniowski B, Lachmann HJ, Whelan CJ, Martinez-Naharro A, Fontana M, Hawkins PN, Gillmore JD, Wechalekar AD. Cohen OC, et al. Among authors: ravichandran s. Amyloid. 2022 Dec;29(4):237-244. doi: 10.1080/13506129.2022.2070741. Epub 2022 May 3. Amyloid. 2022. PMID: 35502644
Long-term outcomes in light chain deposition disease-analysis of a UK cohort.
Ravichandran S, Law S, Mahmood S, Wisniowski B, Foard D, Fontana M, Martinez-Naharro A, Whelan C, Hawkins PN, Gillmore JD, Lachmann HJ, Wechalekar AD. Ravichandran S, et al. Am J Hematol. 2022 Dec;97(12):E444-E446. doi: 10.1002/ajh.26725. Epub 2022 Sep 24. Am J Hematol. 2022. PMID: 36088630 Free article. No abstract available.
372 results